Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Small molecule inhibitors of the growth regulatory mTOR complexes that can ablate both the mTORC1 and mTORC2 signaling functions show great clinical potential as targeted therapeutics for the treatment of many types of cancer, based on preclinical studies.